Evidence map›Paper›PMID 18722489›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2008

Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.

Amit K Sharma, Li Zhang, Shu Li, David L Kelly, Valery Yu Alakhov, Elena V Batrakova, Alexander V Kabanov

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Pluronics and MDR reversal: an update.Molecular pharmaceutics · 2014
    Review
  16. Article
  17. Review
  18. Review
  19. Can nanomedicines kill cancer stem cells?Advanced drug delivery reviews · 2013
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Amit K SharmaCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-5830, USA.
Li Zhang
Shu Li
David L Kelly
Valery Yu Alakhov
Elena V Batrakova
Alexander V Kabanov
University of Nebraska Medical Center · USLomonosov Moscow State University · RUNebraska Medical Center · USSecond Military Medical University · CN

Funding

Pluronic Block Copolymers in Drug Resistant CancerR01CA089225 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KABANOV, ALEXANDER V · 2001 to 2011
$2.2M
NCI NIH HHS CA89225NCI NIH HHS R01 CA089225
6 · The paper itself

Abstract

Doxorubicin (Dox) incorporated in nanosized polymeric micelles, SP1049C, has shown promise as monotherapy in patients with advanced esophageal carcinoma. The formulation contains amphiphilic block copolymers, Pluronics, that exhibit the unique ability to chemosensitize multidrug resistant (MDR) tumors by inhibiting P-glycoprotein (Pgp) drug efflux system and enhancing pro-apoptotic signaling in cancer cells. This work evaluates whether a representative block copolymer, Pluronic P85 (P85) can also prevent development of Dox-induced MDR in leukemia cells. For in vitro studies murine lymphocytic leukemia cells (P388) were exposed to increasing concentrations of Dox with/without P85. For in vivo studies, BDF1 mice bearing P388 ascite were treated with Dox or Dox/P85. The selected P388 cell sublines and ascitic tumor-derived cells were characterized for Pgp expression and functional activity (RT-PCR, Western Blot, rhodamine 123 accumulation) as well as Dox resistance (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay). The global gene expression was determined by oligonucleotide gene microarrays. We demonstrated that P85 prevented development of MDR1 phenotype in leukemia cells in vitro and in vivo as determined by Pgp expression and functional assays of the selected cells. Cells selected with Dox in the presence of P85 in vitro and in vivo exhibited some increases in IC(50) values compared to parental cells, but these values were much less than IC(50) in respective cells selected with the drug alone. In addition to mdr1, P85 abolished alterations of genes implicated in apoptosis, drug metabolism, stress response, molecular transport and tumorigenesis. In conclusion, Pluronic formulation can prevent development of MDR in leukemia cells in vitro and in vivo.

Indexed as

MicellesAnimalsAntibiotics, AntineoplasticApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorDose-Response Relationship, DrugDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleFluorescent DyesGenes, MDRInhibitory Concentration 50Leukemia P388MiceAntibiotics, AntineoplasticATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinFluorescent DyesMicellespluronic block copolymer p85PoloxaleneRhodamine 123Surface-Active Agents

Identifiers

PMID18722489
PMCPMC2711209
OpenAlexW2085327175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.